Head-to-head evidence
BEBT-109 vs H002
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
BEBT-109
Developed by BeBetter Med
NCT06001671 · Phase 1 · completed
This was a small, single-arm, dose-escalation study with no control group and effectively no blinding of participants or investigators; it was designed to find a tolerable dose, not to test whether the drug worked, and results have not yet been reported.
Next expected readout: June 2027 · NCT06514027 (registry estimate)
H002
Developed by RedCloud Bio
NCT05519293 · Phase 1/2 · status unknown
A non-randomized, open-label, sequential-cohort phase 1/2 study of H002 with an estimated 76 participants and no results posted to the registry. With no comparator arm and no posted results, this is weak evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BEBT-109's landscape · H002's landscape